Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients.


Journal

Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479

Informations de publication

Date de publication:
01 2021
Historique:
received: 01 08 2020
accepted: 17 09 2020
pubmed: 17 11 2020
medline: 10 2 2021
entrez: 16 11 2020
Statut: ppublish

Résumé

Several articles reported the existence of an association between ABO blood groups and COVID-19 susceptibility. Group A and group O individuals showed a higher and lower risk, respectively, of becoming infected. No association was observed between ABO groups and mortality. To verify this association, we performed a retrospective study of two cohorts of patients with different demographic and clinical characteristics. A total of 854 regular blood donors were recruited for convalescent plasma donation after recovering from a mild COVID-19 infection, and a group of 965 patients more severely affected who were transfused during hospitalisation were also included. We also investigated the potential role of the different risk factors on patient outcome and death. To eliminate the confounding effect of risk factors on mortality, a propensity score analysis was performed. Blood group A and blood group O COVID-19 blood donors showed a higher and lower risk, respectively, for acquiring COVID-19. In contrast, this association was not found in the group of patients transfused during hospitalisation, probably due to the great differences in demographic and clinical characteristics between the two groups. Regarding severity, age was one of the most significant risk factors. ABO blood groups were also seen to represent important risk factors for COVID-19 severity and mortality. Mortality risk in group A individuals was significantly higher than in group O individuals (OR: 1.75, 95% CI: 1.22-2.51). The association between the ABO blood groups and the susceptibility to acquire COVID-19 infection was confirmed in the group of blood donors. ABO blood groups were also associated to COVID-19 severity and mortality in the group of patients transfused during hospitalisation. Therefore, blood groups A and O are two important factors to be considered when evaluating the prognosis of patients with COVID-19.

Sections du résumé

BACKGROUND
Several articles reported the existence of an association between ABO blood groups and COVID-19 susceptibility. Group A and group O individuals showed a higher and lower risk, respectively, of becoming infected. No association was observed between ABO groups and mortality. To verify this association, we performed a retrospective study of two cohorts of patients with different demographic and clinical characteristics.
MATERIAL AND METHODS
A total of 854 regular blood donors were recruited for convalescent plasma donation after recovering from a mild COVID-19 infection, and a group of 965 patients more severely affected who were transfused during hospitalisation were also included. We also investigated the potential role of the different risk factors on patient outcome and death. To eliminate the confounding effect of risk factors on mortality, a propensity score analysis was performed.
RESULTS
Blood group A and blood group O COVID-19 blood donors showed a higher and lower risk, respectively, for acquiring COVID-19. In contrast, this association was not found in the group of patients transfused during hospitalisation, probably due to the great differences in demographic and clinical characteristics between the two groups. Regarding severity, age was one of the most significant risk factors. ABO blood groups were also seen to represent important risk factors for COVID-19 severity and mortality. Mortality risk in group A individuals was significantly higher than in group O individuals (OR: 1.75, 95% CI: 1.22-2.51).
DISCUSSION
The association between the ABO blood groups and the susceptibility to acquire COVID-19 infection was confirmed in the group of blood donors. ABO blood groups were also associated to COVID-19 severity and mortality in the group of patients transfused during hospitalisation. Therefore, blood groups A and O are two important factors to be considered when evaluating the prognosis of patients with COVID-19.

Identifiants

pubmed: 33196417
pii: 2020.0256-20
doi: 10.2450/2020.0256-20
pmc: PMC7850930
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-63

Références

Br J Haematol. 2020 Jul;190(2):e93-e94
pubmed: 32453863
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Commun. 2020 Nov 13;11(1):5761
pubmed: 33188185
Br J Haematol. 2005 Sep;130(6):954-63
pubmed: 16156865
Ann Hematol. 2020 Sep;99(9):2113-2118
pubmed: 32656591
Transfusion. 2020 Aug;60(8):1883-1884
pubmed: 32562280
Br J Haematol. 2020 Aug;190(4):e204-e208
pubmed: 32609874
Clin Chim Acta. 2020 Oct;509:220-223
pubmed: 32562665
Eur J Prev Cardiol. 2020 Sep;27(13):1436-1437
pubmed: 32343152
J Thromb Haemost. 2008 Jan;6(1):62-9
pubmed: 17973651
J Clin Invest. 2013 Mar;123(3):958-65
pubmed: 23454758
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
Br J Haematol. 2020 Jul;190(1):24-27
pubmed: 32379894
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
Vox Sang. 2021 Jan;116(1):15-17
pubmed: 32965025
JAMA. 2020 Feb 4;323(5):466-467
pubmed: 31922529
Eur J Hum Genet. 2020 Jun;28(6):715-718
pubmed: 32404885
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264

Auteurs

Eduardo Muñiz-Diaz (E)

Immunohematology Laboratory, Banc de Sang i Teixits (BST), Barcelona, Spain.

Jaume Llopis (J)

Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain.

Rafael Parra (R)

BST-Vall d'Hebrón, Hospital Vall d'Hebrón, Barcelona, Spain.

Imma Roig (I)

Hospital Parc Taulí, Sabadell, Clínica Quirón, Barcelona, Spain.

Gonzalo Ferrer (G)

BST-Sant Pau, Hospital de Sant Pau, Barcelona, Spain.

Joan Grifols (J)

BST-Badalona, Hospital Germans Tries, Barcelona, Spain.

Anna Millán (A)

BST-Girona, Hospital Josep Trueta, Girona, Spain.

Gabriela Ene (G)

BST-Hospital del Mar, Barcelona, Spain.

Laia Ramiro (L)

BST-Tarragona, Hospital Joan XXIII, Tarragona, Spain.

Laura Maglio (L)

BST-Manresa, Hospital Sant Joan de Deu, Manresa, Spain.

Nadia García (N)

BST-Bellvitge, Hospital de Bellvitge, Barcelona, Spain.

Asunción Pinacho (A)

BST-Lleida, Hospital Arnau de Vilanova, Lleida, Spain.

Anny Jaramillo (A)

BST-Terrassa, Mutua de Terrassa, Terrassa, Spain.

Agustí Peró (A)

BST-Reus, Hospital Sant Joan de Reus, Reus, Spain.

Gonzalo Artaza (G)

Hospital General de Catalunya, Barcelona, Spain.

Roser Vallés (R)

BST-Barcelona, Central Services, Barcelona, Spain.

Silvia Sauleda (S)

BST-Barcelona, Central Services, Barcelona, Spain.

LLuís Puig (L)

BST-Barcelona, Central Services, Barcelona, Spain.

Enric Contreras (E)

BST-Barcelona, Central Services, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH